Shares of Eli Lilly LLY rose nearly 2% on Thursday after the company announced that a late-stage study evaluating its ...

Dec 10 (Reuters) - French biotech company Abivax's shares rose by over 20% on Wednesday on market rumours that U.S. pharma ...

The drugmaker is betting big on retatrutide as the next pillar of its obesity portfolio after its weight loss injection ...

Eli Lilly is investing $6B in a Huntsville, Ala., plant to make weight-loss and other medicines. Here’s what we know about ...

Eli Lilly’s “triple g” drug helped patients lose about 28.7% of their body weight while also reducing pain associated with ...

The pharmaceutical stock can still deliver.

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

The maker of Zepbound reported results from a study of retatrutide, which targets three hormones in the body and led to much more weight loss than any approved drug.

Eli Lilly (LLY) closed the most recent trading day at $1,027.51, moving +1.8% from the previous trading session. This change outpaced the S&P 500's 1.07% loss on the day. At the same time, the Dow ...

Eli Lilly and Company (NYSE:LLY) is one of the best pharma stocks to invest in. On December 7, Eli Lilly and Company ...

Step aside, semaglutide—retatrutide is showing the most impressive weight loss results of any obesity drug to date.

In an added benefit, more than one in eight people taking the highest dose of Retratrutide were completely free of arthritic ...